Suggested Reading
This section provides a listing of recent articles relating to psoriasis and psoriatic arthritis, as well as references from our continuing education articles and activities. References include links to PubMed and cover such topics as clinical guidelines and consensus statements, comorbid diseases, safety and monitoring for systemic agents, and updates on new agents and those in clinical development.
Guidelines
- British Association of Dermatologists' guidelines for biologic interventions for psoriasis 2009.
Smith CH, Anstey AV, Barker JN, et al. British Association of Dermatologists' guidelines for biologic interventions for psoriasis 2009. Br J Dermatol. 2009;161:987-1019.
View Item
- European S3-guidelines on the systemic treatment of psoriasis vulgaris.
Pathirana D, Ormerod AD, Saiag P, et al. European S3-guidelines on the systemic treatment of psoriasis vulgaris. J Eur Acad Dermatol Venereol. 2009;23 Suppl 2:1-70.
View Item
- From the Medical Board of the National Psoriasis Foundation: monitoring and vaccinations in patients treated with biologics for psoriasis.
Lebwohl M, Bagel J, Gelfand JM, et al. From the Medical Board of the National Psoriasis Foundation: monitoring and vaccinations in patients treated with biologics for psoriasis. J Am Acad Dermatol. 2008;58:94-105.
View Item
- Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics.
Menter A, Gottlieb A, Feldman SR, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol. 2008;58:826-850.
View Item
- Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics.
Gottlieb A, Korman NJ, Gordon KB, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics. J Am Acad Dermatol. 2008;58:851-864.
View Item
- Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 3. Guidelines of care for the management and treatment of psoriasis with topical therapies.
Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 3. Guidelines of care for the management and treatment of psoriasis with topical therapies. J Am Acad Dermatol. 2009;60:643-659.
View Item
- Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents.
Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents. J Am Acad Dermatol. 2009;61:451-485.
View Item
- Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 5. Guidelines of care for the treatment of psoriasis with phototherapy and photochemotherapy.
Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 5. Guidelines of care for the treatment of psoriasis with phototherapy and photochemotherapy. J Am Acad Dermatol. 2010; 62:114-135.
View Item
- National Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screening.
Kimball AB, Gladman D, Gelfand JM, et al. National Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screening. J Am Acad Dermatol. 2008;58:1031-1042.
View Item
Selected References
- A safety assessment of tumor necrosis factor antagonists during pregnancy: a review of the Food and Drug Administration database.
Carter JD, Ladhani A, Ricca LR, et al. A safety assessment of tumor necrosis factor antagonists during pregnancy: a review of the Food and Drug Administration database. J Rheumatol. 2009;36:635-641.
View Item
- A series of critically challenging case scenarios in moderate to severe psoriasis: a Delphi consensus approach.
Strober B, Berger E, Cather J, et al. A series of critically challenging case scenarios in moderate to severe psoriasis: a Delphi consensus approach. J Am Acad Dermatol. 2009;61:S1-S46.
View Item
- Averting inflammation by targetting the cytokine environment.
Kopf M, Bachmann MF, Marsland BJ. Averting inflammation by targetting the cytokine environment. Nat Rev Drug Discov. 2010;9:703-718.
View Item
- Cracking the cytokine code in psoriasis.
Nickoloff BJ. Cracking the cytokine code in psoriasis. Nat Med. 2007;13:242-244.
View Item
- Impact of psoriasis on quality of life. Results of a 1998 National Psoriasis Foundation patient-membership survey.
Krueger G, Koo J, Lebwohl M, et al. Impact of psoriasis on quality of life. Results of a 1998 National Psoriasis Foundation patient-membership survey. Arch Dermatol. 2001;137:280-284.
View Item
- Insurance: Health Insurance Action Center.
National Psoriasis Foundation. Insurance: Health Insurance Action Center. Available at: http://www.psoriasis.org/netcommunity/Page.aspx?pid=1269. January 2010. Accessed August 24, 2010.
View Item
- Methotrexate and psoriasis: 2009 National Psoriasis Foundation Consensus Conference.
Kalb RE, Strober B, Weinstein G, et al. Methotrexate and psoriasis: 2009 National Psoriasis Foundation Consensus Conference. J Am Acad Dermatol. 2009;60:824-837.
View Item
- National Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screening.
Kimball AB, Gladman D, Gelfand JM, et al. National Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screening. J Am Acad Dermatol. 2008;58:1031-1042.
View Item
- Potentially modifiable risk factors for adverse pregnancy outcomes in women with psoriasis.
Bandoli G, Johnson DL, Jones KL, et al. Potentially modifiable risk factors for adverse pregnancy outcomes in women with psoriasis. Br J Dermatol. 2010;163:334-339.
View Item
- Report on the psycho-social impacts of psoriasis.
National Psoriasis Foundation. Report on the psycho-social impacts of psoriasis. 2009. Available at: www.psoriasis.org/survey. Accessed August 22, 2010.
View Item
- Risk of myocardial infarction in patients with psoriasis.
Gelfand JM, Neimann AL, Shin DB, et al. Risk of myocardial infarction in patients with psoriasis. JAMA. 2006;296:1735-1741.
View Item
- The combination of etanercept and methotrexate increases the effectiveness of treatment in active psoriasis despite inadequate effect of methotrexate therapy.
Zachariae C, Mork NJ, Reunala T, et al. The combination of etanercept and methotrexate increases the effectiveness of treatment in active psoriasis despite inadequate effect of methotrexate therapy. Acta Derm Venereol. 2008;88:495-501.
View Item
- The Koo-Menter Instrument for Identification of Psoriasis Patients Requiring Systemic Therapy.
Koo J, Menter A. The Koo-Menter Instrument for Identification of Psoriasis Patients Requiring Systemic Therapy. National Psoriasis Foundation Psoriasis Forum. 2003;9(2):6-9.
View Item
- The psoriasis and psoriatic arthritis pocket guide.
National Psoriasis Foundation. The psoriasis and psoriatic arthritis pocket guide. National Psoriasis Foundation, editor. 9-15-2009. National Psoriasis Foundation.
View Item
- Treatment of psoriasis with anti-TNF drugs during pregnancy: case report and review of the literature.
Puig L, Barco D, Alomar A. Treatment of psoriasis with anti-TNF drugs during pregnancy: case report and review of the literature. Dermatology. 2010;220:71-76.
View Item
- Treatment patterns snapshot.
National Psoriasis Foundation. Treatment patterns snapshot. Available at: http://www.psoriasis.org/NetCommunity/Document.Doc?id=383. 2010. Accessed July 26, 2010.
View Item
- Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial.
Gottlieb A, Menter A, Mendelsohn A, et al. Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial. Lancet. 2009;373:633-640.
View Item
- Vaccinations in patients with immune-mediated inflammatory diseases.
Rahier JF, Moutschen M, Van GA, et al. Vaccinations in patients with immune-mediated inflammatory diseases. Rheumatology (Oxford). 2010;49:1815-1827.
View Item
